• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Is Huachansu Beneficial in Treating Advanced Non-Small-Cell Lung Cancer? Evidence from a Meta-Analysis of Its Efficacy Combined with Chemotherapy
【2h】

Is Huachansu Beneficial in Treating Advanced Non-Small-Cell Lung Cancer? Evidence from a Meta-Analysis of Its Efficacy Combined with Chemotherapy

机译：华蟾素对治疗晚期非小细胞肺癌有益吗？联合化疗疗效的荟萃分析提供的证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Huachansu, the sterilized water extract of Bufo bufo gargarizans toad skin, is used in China to alleviate the side-effects and enhance the therapeutic effect of chemotherapy in advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to assess Huachansu's efficacy. Methods. We extensively searched electronic databases (CENTRAL, EMBASE, MEDLINE, CBM, Cochrane Library, CNKI, CEBM, WFDP, CSCD, CSTD, and IPA) for randomized controlled trials containing Huachansu plus chemotherapy as the test group and chemotherapy as the control group. Seventeen trials were selected based on the selection criteria. The pooled relative ratio (RR) of indicators with 95% confidence interval (95% CI) was calculated for efficacy evaluation. Results. The meta-analysis demonstrated a statistically significant improvement in objective tumor response, one-year survival, Karnofsky performance status, pain relief, and alleviation of severe side-effects (nausea and vomiting, leukocytopenia) in the test group as compared to the control group, but no significant difference in thrombocytopenia. Conclusions. This study demonstrated the efficacy of Huachansu combined with chemotherapy in the treatment of advanced NSCLC. However, limitations exist and high-quality trials are needed for further verification.
机译：背景。华蟾素是蟾蜍蟾蜍皮肤的无菌水提取物，在中国用于减轻副作用，并增强化疗对晚期非小细胞肺癌（NSCLC）的治疗作用。我们进行了荟萃分析以评估华蟾素的疗效。方法。我们广泛搜索了电子数据库（CENTRAL，EMBASE，MEDLINE，CBM，Cochrane库，CNKI，CEBM，WFDP，CSCD，CSTD和IPA）进行随机对照试验，其中以Huachansu加化疗为对照组，以化疗为对照组。根据选择标准选择了十七项试验。计算具有95％置信区间（95％CI）的指标的合并相对比率（RR），以进行功效评估。结果。荟萃分析显示，与对照组相比，试验组的客观肿瘤反应，一年生存率，卡诺夫斯基机能状态，疼痛缓解和严重副作用（恶心，呕吐，白细胞减少症）的缓解有统计学意义的改善，但血小板减少症无明显差异。结论。这项研究证明了华蟾素联合化疗治疗晚期非小细胞肺癌的疗效。但是，存在局限性，需要高质量的试验来进行进一步的验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号